FDA Announces Draft Guidance on Outsourcing Facility Sales

The U.S. Food and Drug Administration (FDA) issued a draft guidance document, June 27, that describes FDA’s current thinking on the prohibition of wholesaling human drugs by a 503B outsourcing facility under the Food, Drugs, and Cosmetics Act (FDCA)….
By: Quarles & Brady LLP
Previous Story

FTC Announces Enforcement Action Against 1Health.io for Inadequate Protection of Genetic Data and Unfair Privacy Policy Changes

Next Story

HHS-OIG Issues FAQ Guidance Related to Pharmacy Benefit Manager Arrangements